Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2006-11-07
2006-11-07
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S001110, C424S001650, C424S009200, C435S029000
Reexamination Certificate
active
07132096
ABSTRACT:
The present invention provides methods for inhibiting growth of a bacterium which consists essentially of contacting the bacterium with gemfibrozil, or a related compound, in a concentration effective to inhibit growth of the bacterium. This invention also provides related screening and therapeutic methods.
REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 4163859 (1979-08-01), Sprenger, deceased
patent: 4859703 (1989-08-01), Krause
patent: 4891220 (1990-01-01), Donzis
patent: 5422372 (1995-06-01), Silverstein et al.
patent: 5837480 (1998-11-01), Sacchettini et al.
patent: 6531291 (2003-03-01), Kabbash et al.
patent: 6713043 (2004-03-01), Kabbash et al.
patent: 6881553 (2005-04-01), Kabbash et al.
patent: 2004/0266838 (2004-12-01), Kabbash et al.
patent: WO 9303716 (1993-03-01), None
patent: WO 9937800 (1999-07-01), None
Armani, G. et al. (1972) Synthesis and Pharmacological Activity of Some Chlorpenesin Phenoxyalkanoates,Farmaco-Ed.Sc. vol. 27, pp. 870-875.
Chak, W. et al. (1981) Effects of Metabolic Inhibitors on Extracellular Fructosyltransferase Production inActinomyces Viscosus, Infection and Immunityvol. 34(3), pp. 930-937.
Gao, P. et al. (1991) Inhibition of Organic Anion Transport in J774 Macrophage-like Cells Potentiates the Ability of Norfloxacin to Inhibit the Intracellular Growth of Listeria-monocytogenes in these Cells,Program and Abstracts of the Interscience Conference on Antimicrobialvol. 31, pp. 106.
Kabara, J. J. (1976) The Effect of Clofibrate and other Hypocholesteremic Drugs on Microorganisms,Arteryvol. 2(6), pp. 497-518.
Kusaka, T. et al. (1976) Studies on Uptake of Fatty Acids into Mycobacterial Cells,J. Kawasaki Medical Journalvol. 1(4), pp. 153-162.
Powanda, M.C. et al. (1976) Protective Effect of Clofibrate Against S. Pneumoniae Infection in Rats,Proceedings of the Society for Experimental Biology and Medicine152(3), pp. 437-440.
Rudin, D.E. et al. (1992) Gemfobrozil Enhances the Listeriacidal Effects of Fluoroquinolone Antibiotics in J774 Macrophages,J. Exp. Med. vol. 176, pp. 1439-1447.
Smith, P.F. et al. (1966) Growth Inhibition of Mycoplasma by Inhibitors of Polyterpene Biosynthesis and its Reversal by Cholesterol,J. of Bacteriology9(5), pp. 1854-1858; and.
Yajko, D.M. et al. (1995) Gemfibrozil Enhances the Intracellular Activity of Ciprofloxacin AgainstMycobacterium aviumComplex (MAC), Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy.
U.S. Appl. No. 09/438,144, filed Nov. 10, 1999, Kabbash et al.
The Merck Index, 10thEd., Merck & Co., Inc., Rahway, New Jersey, 1983, No. 4246.
Vernon et al. (1984) the Presence of Essential Arginine Residues at the NADPH-Binding Sites of β-Ketoacyl Reductase, And Enoyl Reduciase Domains of the Multifunctional Fatty Acid Synthetase of Chicken Liver,Biochim et Biophys. Act. vol. 788, pp. 124-131.
Clements et a. (1982) Irreversible Inhibition of Fatty Acid Synthase From Rat Mammary Gland With S-(4-bromo-2,3-dioxobutyl)-CoA.Biochem. J. vol. 207, pp. 291-296.
Bergler, H. et al. (1996) The enoyl-[acyl-carrier-protein] reductase (Fabl) ofEscherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.Eur. J. Biochem. vol. 242, pp. 689-694.
Heath, R.J. and Rock, C.O. (1996) Regulation of Fatty Acid Elongation and Initiation by Acyl-Acyl Carrier Protein inEscherichia col. J. Biol. Chem. vol. 271, No. 4, pp. 1833-1836.
Cardon, J. W. and Hammes, G.G. (1983) Kinetic and Structural Investigation of Acyl-binding Sites on Avian Fatty Acid Synthase.J. Biol. Chem. vol. 258, No. 8, pp. 4802-4807.
Amigo, I., et al. (1992) Subcellular distribution and characteristics of ciprofibroyl-CoA synthetase in rat liver.Biochem. J. vol. 284, pp. 283-287.
Bronfman, M., et al. (1992) Hypolipidaemic drugs are activated to acyl-CoA esters in isolated rat hepatocytes.Biochem. J. vol. 284, pp. 289-295.
Urrea, R. and Bronfman, M. (1996) Species Differences in the Intracellular Distribution of Ciprofibroyl-CoA hydrolase. Implications for peroxisome proliferation. FEBS Letters. vol. 389, pp. 219-223.
Hashimoto, et al. (1997) Effect of gemfibrozil on centrifugal behavior of rat peroxisomes and activities of peroxisomal enzymes involved in lipid metabolism.Bio Pharm. Bull. vol. 20, No. 4, pp. 315-321.
Baldock et al., (1996) A Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase.Science. vol. 274, pp. 2107-2110.
Partial European Search Report, dated Jan. 27, 2005 for European Application No. EP 97 914 817.8.
Della-Latta Phyllis
Kabbash Christina
Shuman Howard A.
Silverstein Samuel C.
Cooper & Dunham LLP
Jones Dameron L.
The Trustees of Columbia University in the City of New York
White, Esq. John P.
LandOfFree
Antimicrobial activity of gemfibrozil does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antimicrobial activity of gemfibrozil, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antimicrobial activity of gemfibrozil will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3627735